Novel therapeutic targets and drugs in Lupus, Scleroderma and Sjogren diseases - Biowebspin | Biowebspin
Logo Biowebspin


The worldwide platform to find industrial partners and funding

External open innovation partner programNovel therapeutic targets and drugs in Lupus, Scleroderma and Sjogren diseases

Are you working on immuno-inflammation? Have you identified new targets or drugs for the treatment of Lupus, Scleroderma or Sjogren diseases? Are you interested in partnering with Servier to translate your new science into a new medicine?
What we are looking for

Autoimmune diseases are characterized by an aberrant activation of the immune system, which results in immune responses directed at self-antigens. We are looking for proposals to identify new therapeutic targets and drugs for the treatment of Lupus, Scleroderma or Sjogren diseases or that will result in the induction or restoration of immune tolerance.

At the preclinical stage, new validated molecular targets and drugs (targets to hit and later stages) must be supported by clear scientific data deriving from in vitro (compulsory), ex vivo, or animal models (a plus). Molecular targets identified in clinical trials (up to Phase II clinical trial) shall also be considered. Marketed drugs (drug repositioning) are excluded.

What we offer

All proposals will be assessed by our Research & Development team. Based on the level of interest within our research portfolio and the strategic fit of the proposals into Servier long-term research focus, we will enter into discussion with selected candidate(s), potentially leading to funding and partnership agreements.

Proponents that submit proposals of interest will be contacted within 6 to 8 weeks of submission to clarify additional details concerning the underlying science as well as intellectual property rights, timelines, etc.

What to submit

Submit your proposal online (it takes about 15 minutes) in a form and length that is sufficient to provide the substance of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project and how that knowledge could be supplemented (i.e., what is additionally required to complete the project). Additional information, including references or other materials should be attached to facilitate the evaluation process.

Privacy, confidentiality & FAQ

While Servier will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.

If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA).


Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.

Biowebspin is a matchmaking platform between academia & industry. Biowebspin is not involved in the IP discussion and is not charging any success or license fees. Your «Open Innovation» opportunities on Biowebspin are only visible by industrials and the Biowebspin team. You can remove your data at any time. Biowebspin strongly recommends that you do not enter any confidential data or if you do so, that your technology transfer office agrees the submission of your pre-proposal on Biowebspin. If you directly submit your pre-proposal on an industrial partner website, you will agree their terms, conditions and privacy policy of our industrial partner website. Biowebspin is not responsible for the content, accuracy, or opinion of its industrial partner website. As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Contact us for more information about the terms and conditions of the matchmaking service of Biowebspin.


Servier is a leading pharmaceutical company headquartered in France. Committed to improving health worldwide, corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiology, metabolism, neuropsychiatry, oncology and rheumatology.

Privately own company, Servier reinvests 25% of its turnover (€3.9 billion in 2015) in Research and development and all its profits in its growth.

About Biowebspin:

Biowebspin is the #1 academia-industry partnering network in Life Sciences.
For academics, Biowebspin is the platform to find industrial partners and funding for their research projects matching R&D programs of more than 500 leading Life Sciences companies and foundations.

Check if one program will fit your researches for industrial collaboration and funding